Targets › CHRN
2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 1; Metabolic and endocrine, Other.
Open in Phaseline: the race on CHRN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Yonsei University | Chonline Alphoscerate Cholinergic neuroprotective agent; precursor to phosphatidylcholine | CHRN | Phase 4 | Type2 Diabetes With Depressive Mood | – |
| Universitas Padjadjaran | Sugammadex Selective relaxant binding agent that directly encapsulates and inactivates rocuronium | CHRN | Phase 1 | Neuromuscular Blocking Agents | – |
Type2 Diabetes With Depressive Mood (1) Neuromuscular Blocking Agents (1)
small molecule (2)
Yonsei University (1) Universitas Padjadjaran (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.